The presence of SSX2 expression in so many tumor types suggested that this antigen is upregulated in cancer independently from fusion events with SS18, perhaps by alterations in methylation status or by the overexpression of SSX2 transcriptional activators. The gene discussed is SSX2; the disease is cancer.